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ABSTRACT
Background: Thymidylate synthase (TS), one of the key enzymes for thymidine 
synthesis, is a target of pemetrexed (PEM), a key agent for the systemic therapy of 
malignant pleural mesothelioma (MPM) and its overexpression has been correlated 
to PEM-resistance. In MPM, experimental data report activation of the c-SRC tyrosine 
kinase suggesting it as a potential target to be further investigated.
Results: MPM cell lines showed different sensitivity, being MSTO the most 
and REN the least sensitive to PEM. REN cells showed high levels of both TS and 
SRC: dasatinib inhibited SRC activation and suppressed TS protein expression, 
starting from 100 nM dose, blocking the PEM-induced up regulation of TS protein 
levels. Dasatinib treatment impaired cells migration, and both sequential and co-
administration with PEM significantly increased apoptosis. Dasatinib pretreatment 
improved sensitivity to PEM, downregulated TS promoter activity and, in association 
with PEM, modulated the downstream PI3K-Akt-mTOR signaling. 
Cell lines and Methods: In three MPM cell lines (MPP89, REN and MSTO), the 
effects of c-SRC inhibition, in correlation with TS expression and PEM sensitivity, 
were evaluated. PEM and dasatinib, a SRC inhibitor, were administered as single 
agents, in combination or sequentially. Cell viability, apoptosis and migration, as 
well as TS expression and SRC activation have been assessed. 
Conclusions: These data indicate that dasatinib sensitizes mesothelioma cells 
to PEM through TS down-regulation.
INTRODUCTION
Malignant pleural mesothelioma (MPM) is a highly 
aggressive tumor strongly linked to asbestos exposure 
[1, 2]. MPM mortality rates are estimated to increase by 
5–10% per year in most industrialized countries, with an 
expected peak over the period 2020–2050 [3]. In advanced 
disease, chemotherapy as single agent (PEM) or in doublet 
combinations (PEM, cisplatin), despite inducing tumor 
shrinkage and improving overall survival, has mainly a 
palliative role with a median survival in advanced disease 
ranging between 9 and 17 months [4].
Intrinsic and acquired resistance mechanisms, 
including high thymidylate synthase (TS) expression, may 
be responsible for the limited efficacy of PEM in MPM 
[5] and, in several cell lines, the induction of resistance to 
PEM was associated with increased levels of TS mRNA 
expression [6]. A phase III study reported an inferior 
activity in terms of overall survival of the combination of 
cisplatin and PEM compared to cisplatin and gemcitabine 
for squamous cell lung carcinoma and opposite data for 
non-squamous non-small cell lung cancer [7] and this 
differential efficacy was related to TS mRNA expression, 
being higher in squamous cell carcinoma of the lung [8, 9].
Other anticancer agents may potentially modulate 
PEM anti-proliferative activity. In pancreatic carcinoma 
cells the inhibition of SRC, a Src Family Kinase (SFK) 
member strongly activated in many solid tumors and 
controlling key processes in tumor development, was 
shown to revert the 5-FU resistance of cancer cells through 
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indirect TS regulation [10]. SFKs are activated in MPM 
cell lines and tissue specimens when compared with 
normal mesothelial cells [11]. In MPM cell lines, SRC 
inhibitors led to apoptosis, cell cycle arrest and decreased 
migration and invasion [12] In NSCLC cell lines, the 
synergistic effect of PEM in combination with dasatinib, 
an oral dual Bcr/Abl and SFKs competitive ATP inhibitor, 
has already been reported [13].
The present study investigated whether SRC 
inhibition may increase, or restore, the sensitivity to PEM 
in MPM cell lines. This is the first study in MPM cell lines 
reporting the benefit of a SRC-inhibitor in suppressing the 
increased TS expression that occurs as a compensatory 
response to PEM.
RESULTS
Characterization of TS expression/localization 
and SRC activation in MPM cell lines
Malignant pleural mesothelioma (MPM) histology 
includes three phenotypes: epithelioid, sarcomatoid 
or biphasic (combination of the two histotypes). The 
sarcomatoid histotype is the least common (5% of the 
patients), immortalized sarcomatoid cell lines are very 
difficult to obtain, and some of those commercially 
available lack clear-cut distinct features. The MPM 
cell lines we analyzed include the two most commonly 
documented histotypes:  epithelioid (REN, MPP89) and 
biphasic (MSTO). 
Expression and localization of TS and both total and 
activated (phospho Tyr 419, pSRC) SRC baseline levels 
were investigated in untreated MPM cells. Differences 
in both TS and pSRC expression and localization were 
detected: immunofluorescence showed a strong expression 
of pSRC at the cell membrane (SRC Tyr419, green) and 
differential TS nuclear and/or cytoplasmic expression (TS, 
green) in the considered cell lines. TS expression was 
homogeneously detected in the cytoplasm of all cell lines, 
extended to the nucleus in MSTO and MPP89. Conversely, 
pSRC was differentially detected being localized in the 
cytoplasm of MSTO cells and almost exclusively in the 
nucleus of MPP89 cells. In REN cells, pSRC was detected 
in both the cytoplasm (including the cell membrane) and 
the nucleus (Figure 1A). Baseline SRC and TS expression 
were also assessed at transcriptional (Figure 1B) and 
protein levels (Figure 1C): TS gene expression did not 
show evident differences between MPP89 and MSTO cell 
lines, in contrast REN expressed about double amount of 
TS mRNA.  TS protein levels correlated with the mRNA 
levels, being high in REN and scanty in both MPP89 and 
MSTO. This correlation mRNA-protein was not retained 
for SRC expression: SRC gene and protein expression 
levels were not associated and SRC protein, both total 
and phosphorylated forms, was higher in REN and MSTO 
compared to MPP89.
Pharmacological interaction between dasatinib 
and PEM
The effect of PEM and dasatinib on the viability of 
MPM cells was investigated. PEM weakly affected cell 
viability in MPP89 and REN cells compared to untreated, 
while MSTO cells showed the strongest sensitivity, even 
at lower PEM concentrations. Because of the documented 
PEM activity, in this cell line experiments lasted after 
48 hours. According to the approach reported in the 
Material and Method section, the best-fit estimate of the 
IC50 for PEM, when combined with dasatinib, was 5 µM 
in REN cells, 1 µM in MPP89 cells and 0.5 µM in MSTO 
cells. The effect of dasatinib was more homogeneous, 
being IC50 values 5 µM in REN and 1 µM in both MPP89 
and MSTO cells. Dose-response curves are shown in 
Figure 2A. In REN and MPP89 cell lines, dasatinib 
shifted the cytostatic activity of PEM to cytotoxic/anti-
proliferative effect. In PEM-sensitive MSTO cell lines, the 
addition of dasatinib significantly reduced cell viability as 
indicated by the lower IC50 values (Figure 2A).
The different efficacy of dasatinib and PEM 
observed in cell viability experiments, when administered 
either as single or combined agents, prompted the 
investigation on apoptosis. After PEM administration, 
Annexin V-Propidium Iodide staining showed a significant 
increase of apoptosis in MSTO cells at 48 hours, while a 
weaker effect was detected in REN and MPP89 at 72 hours 
(Figure 2B). Conversely, the proportion of REN and 
MPP89 cell lines undergoing apoptosis was significantly 
higher than after single agent administration, suggesting a 
synergistic effect of these drugs. In contrast, the combined 
treatment in MSTO cells resulted in a reduced apoptotic 
rate (Figure 2B). These results suggest that even the less 
PEM-sensitive MPM cell lines, such as REN and MPP89, 
can be sensitized by the co-administration of dasatinib.
SRC and TS protein expression and 
chemosensitivity correlation
In all MPM cells, dasatinib, alone and in 
combination with PEM, reduced SRC phosphorylation 
in the activating Tyr 419 (Y419) without affecting total 
SRC expression levels. PEM differently increased 
TS expression levels, either alone or in combination 
with dasatinib. In REN cells, dasatinib as single agent 
significantly reduced TS protein expression when 
compared to untreated cells. This suggests a crosstalk 
between TS and SRC pathways and, more specifically, 
dasatinib modulates TS expression (Figure 2C).  
Dasatinib, but not PEM, inhibits MPM cell 
migration 
Since dasatinib induced MPM cell line 
morphological alterations, including cell size reduction 
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and frequently round shape (data not shown), we 
investigated its effect on cell motility and for this purpose 
the wound-healing assay was used. Untreated MPM cells 
were highly motile, being MSTO cells able to repopulate 
the scratched area within eight hours, while REN and 
MPP89 cells repaired the wound within 24–30 hours. In 
presence of dasatinib, cell migration into the wounded 
area was greatly impaired (Figure 2D). Because of the 
lack of information on PEM ability to interfere with 
cell motility, we investigated whether PEM may affect 
the migratory ability of MPM cells. Cells were treated 
with IC50 doses of single agents or of their combination: 
PEM did not affect cell migration and, in combination 
with dasatinib, the migratory inhibition was comparable 
with that of dasatinib alone. These data suggest that PEM 
acts synergistically with dasatinib on proliferation rate 
and in inducing apoptosis, but does not affect, neither 
promoting nor interfering, with the migratory potential.  
Figure 1: Basal TS, pSRC and SRC localization and expression in MPM cells. In all MPM cell lines analyzed, the subcellular 
distribution of both TS and pSRC was detected by confocal microscopy after immunostaining with anti-TS (FITC-green, left panel) and 
anti-pSRC (FITC-green, right panel). Propidium iodide was used to counter stain nuclei, and the images were overlaid to determine both 
TS and pSRC localization within the cell. Confocal series images were taken on an inverted Zeiss LSM510 microscope equipped with 
a Plan-Apochromat 63X/1.4 oil immersion Ph 3 objective (Oberkochen, Germany). Scale bars: 10 μm. (A). Basal TS and SRC genes 
expression was determined by means of quantitative Real Time PCR (B) and TS, SRC and pSRC protein expression was also detected using 
immunoblotting (C). BACT served as housekeeping control.  
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Figure 2: PEM and Dasatinib affect cell viability, apoptosis, TS and SRC protein levels and cell migration. PEM and 
dasatinib efficacy was established in all three MPM cell lines. REN and MPP89 (left and middle panels) were incubated with single and 
combination drugs for 72 hours, while 48 hours were sufficient for MSTO (right panel) (A). The apoptotic rate displayed differential 
responses, among MPM cells, to single and double treatments after 72 (left and middle graph) and 48 (right graph) hours, respectively 
(B). The same incubation times were applied to detect TS, SRC and pSRC protein expression (C). Wound healing assay was employed to 
determine the effect mediated by drugs on cell migration. Compared with untreated, dasatinib treatment abolished cell migration capability 
to heal the scrape after 24 hours in both REN and MPP89 cell lines (left and middle panels), and after 8 hours in MSTO (right panel). Plots 
display the progressive time-depending wound healing, in pixel units (px), under different drugs conditions (D).  
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Dasatinib enhances PEM-induced cytotoxicity 
down-modulating TS expression 
Unexpectedly, in REN cells dasatinib at IC50 reduced 
TS expression (Figure 2C, left panel) and we investigated 
if this effect was SRC-inhibition related. To this 
purpose, REN were treated for 72 hours with increasing 
concentrations of dasatinib (1 nM to 1 µM). The lowest 
dose that completely eliminated SRC phosphorylation 
(100 nM) was also corresponding to the concentration 
that down-regulated TS expression (Figure 3A) and 
TS inhibition was dasatinib concentration dependent 
(Figure 3A, upper panel). To assess dasatinib role at 
the transcriptional level, we isolated the very proximal 
promoter region of TS promoter (−1191+176 bp) and 
cloned in front of the luciferase reporter gene. Stable 
REN cell line clones (REN TS-Prom-1191+176) were 
selected and luciferase activity evaluated after treatment 
with dasatinib. The experiments on two independent REN 
TS-Prom-1191+176 clones, D7 and D9, showed that 
dasatinib impaired luciferase activity both at 24 and at 
48 h (Figure 3A, middle panel), mirroring the endogenous 
TS protein expression pattern (Figure 3A, bottom panel). 
Furthermore, to evaluate the effect of dasatinib and PEM 
combination, the luciferase expression in five different 
REN TS-Prom-1191 + 176 clones that differ among each 
other because of their basal luciferase expression levels, 
was measured. In particular, clones D7 and C8 expressed 
low luciferase levels (< 10000 CPS), in contrast, D9, D2 
and A7 that expressed higher luciferase levels (> 30000 
CPS). After clones pretreatment for 12 hours with 0.5 µM 
dasatinib, all of them lowered the luciferase activity 
in comparison with controls (Figure 3B). Afterwards, 
the cells were sequentially incubated for 72 hours with 
1 µM PEM (PEM), removing (rD→PEM) or maintaining 
(mD→PEM) dasatinib (D) pretreatment. A further 
PEM alone administration (72 hours), without dasatinib 
pretreatment, was also performed. mD→PEM was the 
most valuable treatment in impairing TS transcriptional 
activity. Indeed, in all five clones we observed a significant 
reduction (> 75–80%) of luciferase levels compared to 
untreated condition.  A different pattern was observed after 
PEM addition, alone or upon dasatinib wash out. Those 
clones with basal promoter activation increased luciferase 
activity after PEM treatment; conversely, clones with basal 
high luciferase activity were roughly unaffected by PEM 
treatment. 
These results could be dependent by clone 
conditions, suggesting that in those clones with low basal 
TS promoter activation, the inhibition of TS protein by 
pemetrexed activates a feedback on promoter increasing 
the expression of luciferase, while in clones with massive 
basal activation, the system reaches a plateau level and 
1 µM pemetrexed cannot increase the expression of 
luciferase. Thereby in these conditions, we assessed only 
the signal reduction mediated by dasatinib.
To better understand the specific involvement of 
SRC in this scenario, we transfected TS-promoter reporter 
gene, in the presence or absence of SRC dominant negative 
(K295M, kinase dead), as well as in presence of dasatinib. 
The expression of SRC dominant negative impaired 
luciferase activity, under control of TS-promoter, both 
at 24 and at 48 hours post transfection, indicating direct 
regulation of SRC on TS promoter (Figure 3C). The effect 
of SRC dominant negative was evident also at the protein 
level, reducing endogenous TS protein (Figure 3C). These 
results, independent by dasatinib use, clearly demonstrate 
that SRC controls TS expression through transcriptional 
regulation. 
Different concentrations of both drugs modifies 
apoptosis and SRC/TS mRNA expression 
Dasatinib effect on TS expression suggests a role 
as a sensitizer to PEM treatment. Twenty-four hours 
after REN cells seeding, single agents and sequential 
treatments (72 hours rD → 72 hours PEM and 72 hours 
or mD → 72 hours PEM) were investigated. Cell 
viability assays demonstrated that pretreatment with 
dasatinib significantly decreased PEM IC50, being the 
reduction higher in mD and co-administration conditions. 
Afterwards, we assessed whether pretreatment with 
dasatinib enhanced also the apoptotic event induced by 
PEM. REN cells were incubated with both drugs, as single 
agent or in combination, concomitantly or sequentially, 
either at IC50 dose for each drug or at the reduced dose of 
100 nM for both drugs. The choice of this concentration 
has been justified in Figure 3A, where dasatinib 100 
nM was the lowest concentration that switched off SRC 
phosphorylation and reducing TS expression.
In REN cells treated with IC50 dasatinib, apoptosis 
was not affected, while treatment with PEM at IC50 
increased the apoptotic rate by 11.8% when compared 
to untreated cells. Comparable rates were observed with 
the sequence rD (apoptotic rate 10.3%), and a higher rate 
with the combination of PEM and dasatinib (16%). The 
highest apoptotic effect was observed after sequential mD 
(32.4%; Figure 4A). At 100 nM for both drugs, cell death 
rate was similar: dasatinib alone did not affect apoptosis, 
while PEM alone or the sequence rD, both generated an 
18% apoptotic rate. Differently from the results observed 
testing IC50 doses, the simultaneous administration of 
PEM and dasatinib did not affect cell apoptosis, whereas 
the sequential mD induced a 24% of cell apoptosis 
(Figure 4A). These data indicate that the sequential 
administration mD led to higher efficacy, also when lower 
concentrations of the two drugs were tested. 
In parallel, TS and SRC mRNA expression were 
assessed. The most relevant TS gene expression change 
was observed in dasatinib pre-treated cells (with either 
removal or maintenance of dasatinib at the time of PEM 
addition) with a three-fold increase in TS gene expression 
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level compared to untreated cells (Figure 4B, lower 
panel). At the 100 nM dose, TS expression levels did 
not significantly change after PEM administration, with 
a 1.5 fold up-regulation after dasatinib alone or after the 
sequence rD, and an even down-regulating effect in mD 
sequence (Figure 4B, lower panel). SRC expression did 
not change when drugs were added at IC50, showing only 
an almost two-fold increase in rD sequence. At 100 nM 
dose, SRC expression was strongly (up to five-fold) up-
regulated in dasatinib alone treated cells, three-fold with 
the concomitant administration of dasatinib and PEM and 
had a four-fold increase with the sequence mD (Figure 4B, 
upper panel).
Dasatinib and PEM, at low doses, impair 
intracellular signaling of PI3K-Akt-mTOR 
pathways
Apoptosis and gene expression data analyses 
indicate that TS transcriptional regulation is under the 
Figure 3: Dose-depending efficacy of dasatinib on TS promoter inhibition and SRC direct involvement in TS promoter/
protein modulation. REN cells treatment with scalar dasatinib concentration inhibited TS expression and SRC activation already at 
100 nM concentration. A similar behavior was seen for the TS-promoter (REN TS-Prom-1191 + 176 clones D7 and D9). In particular, in 
each clone, dasatinib reduced TS promoter mediated luciferase activity at 24 and 48 h. This effect was also confirmed at the TS protein 
level (A). To assess the effect of combination of dasatinib and PEM we measured the luciferase expression in five independent REN 
TS- Prom-1191 + 176 clones. After pretreatment for 12 hours with 0.5 µM dasatinib, all clones expressed low levels of luciferase compared 
to controls. Clones were subsequently incubated for 72 hours with PEM at 1 µM (PEM) either removing (rD→PEM) or maintaining 
(mD→PEM) dasatinib pretreatment. An incubation with 72 hours of PEM alone was in parallel carried out. In all the clones examined, 
mD→PEM condition was the most efficient in downregulating TS transcriptional activity (B). The expression of a dominant negative 
form of SRC (SRC K295M) impaired expression of luciferase under control of TS-promoter at both 24 and at 48 h post-transfection. 
Furthermore, the effect of SRC KD K295M was assessed also at the protein level, resulting in a reduction of the endogenous TS protein (C).
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control of an upstream tyrosine kinase, such as SRC. 
Because the differential sensitivity was not related to the 
histological subtype of investigated cell lines, we tested 
putative differences in mutational pattern through NGS 
sequencing of fifty tumor-associated genes. REN cell line 
showed the loss of the tumor suppressor LKB1/STK11, 
an intracellular kinase that converges with PI3K signaling 
to regulate a number of downstream effectors, including 
the mTORC1 complex. LKB1/STK11 is involved in SRC 
signaling [14], as well as in PEM response through mTOR 
pathway [15]. In REN cells, none of the five amplicons of 
LKB1 included in the panel was detected, differently from 
MPP89 and MSTO cells and this finding was supported 
by both qPCR and Western blot experiments. Neither 
LKB1 mRNA nor protein was detected (Supplementary 
Figure 1).
These preliminary observations prompted further 
investigations on the PI3K-Akt-mTOR pathway, with the 
hypothesis that SRC and TS modulation could converge 
in this signaling pathway. Western blot analyses reported 
in Figure 4C show the expression data obtained after 
treatment with both drugs at IC50 doses (upper panel). 
TS protein was always strongly overexpressed, with 
the exception of dasatinib that repressed TS expression. 
SRC phosphorylation was partially restored in the rD 
condition. The PI3K catalytic subunit α (p110-α) was 
strongly expressed in untreated cells as well as following 
single agent dasatinib and PEM. While PI3K-p110-α 
subunit expression was not affected by increasing doses of 
dasatinib, even at 1 µM (data not shown), the concomitant 
administration of dasatinib and PEM and the sequence 
mD resulted in a marked abrogation of p110-α subunit, 
without changes in the expression of the catalytic subunit 
β (p110-β, data not shown). A similar expression pattern 
was also observed for AKT phosphorylation (Ser 473) 
without changes in the total AKT expression levels. The 
phosphorylation of p70S6K was also assessed, but no 
modifications were detected in both single agent and rD 
treatments compared to untreated cells. On the contrary, 
p70S6K phosphorylation was significantly reduced by 
the concomitant administration of dasatinib and PEM 
and eliminated in the mD condition (Figure 4C). Since 
dasatinib induced TS suppression at the dose of 100 nM, 
protein changes in the PI3K-Akt-mTOR pathway 
were further investigated. Dasatinib suppressed SRC 
phosphorylation, decreasing AKT activation and reducing 
p70S6K phosphorylation as well as TS expression 
(Figure 4C, right panel) while mTOR was activated, with 
no changes in the PI3K p110-α expression. The phospho-
mTOR content was semi-quantitatively assessed and 
mTOR phosphorylation was slightly increased following 
the administration of single agent (PEM, dasatinib) or in 
the concomitant administration, but decreased in sequential 
administrations (data not shown). Single agent PEM did 
not influence SRC phosphorylation, but inhibited AKT 
phosphorylation and strongly influenced the activation 
of mTOR–p70S6K pathway, leading to increased TS 
expression (Figure 4C). A similar pattern alteration was 
observed with the combination of dasatinib and PEM, 
along with the expected inhibition of SRC phosphorylation 
secondary to dasatinib. Conversely, sequential treatments 
decreased mTOR phosphorylation and PI3K p110-α 
expression, maintaining AKT phosphorylation and 
surprisingly TS expression at low levels, similar to 
those detected in untreated cells (Figure 4C). SRC 
phosphorylation, as well as p70S6K phosphorylation, was 
suppressed in mD treatments (Figure 4C, lower panel).
DISCUSSION 
In the present study, the potential enhancement 
of PEM anti-tumor effect by dasatinib, a multitargeted 
tyrosine kinase inhibitor, was explored in MPM cell lines. 
Several studies showed an interaction when cytotoxic 
agents are administered simultaneously with tyrosine-
kinase inhibitors [16]. The potential synergistic effect of 
dasatinib on PEM sensitivity was investigated in three 
MPM cell lines showing a differential effect on inhibiting 
downstream effector signaling and cell viability.
PEM inhibits several multiple folate-dependent 
enzymes, including thymidylate synthase (TS), and in non-
small cell lung cancer PEM had a lower antitumor activity 
in squamous when compared to non-squamous histotypes 
[7–9] and this differential activity has been associated to 
higher levels of intracellular TS in squamous histology 
[6, 17]. Strategies to enhance antifolate efficacy include 
the ability of other drugs, among which targeted agents, 
simultaneously or sequentially administered, to decrease 
TS expression levels or in reducing its up-regulation. 
While in MPM there is no evidence of activity of tyrosine 
kinase inhibitors [18, 19], an interaction between c-SRC 
inhibitors and antifolate agents has been reported, mostly 
mediated by TS and c-SRC expression level modulation 
[10, 11, 13, 20, 21]. High basal TS levels characterize 
REN cells as well as reduced sensitivity to PEM and 
loss of LKB1/STK11. LKB1 null tumors are associated 
with clinical aggressiveness as well as with activation of 
SRC pathway, leading to the hypothesis that LKB1 loss 
promotes dependence upon this signaling pathway for 
cell migration [14]. In our study, REN cells had the most 
aggressive behavior with high SRC expression: dasatinib 
inhibited cell migration after wound healing stress, as 
also demonstrated by others [12], even in the presence of 
PEM, which did not modify the impairment of dasatinib-
mediated cell migration. 
Single-agent dasatinib did not show activity in 
unselected previously treated MPM patients [22], and 
in our in vitro data no single agent activity of dasatinib 
was detected in all three MPM cell lines but in REN 
cells it reduced TS protein expression. This modulation 
was also confirmed by luciferase assays and dasatinib 
after at least 12 hours down-modulated luciferase 
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activity under control of TS promoter. In addition, the 
combined administration of PEM and dasatinib, as well 
as the pretreatment with dasatinib, increased the cellular 
response to PEM. The level of luciferase in all five TS 
promoter clones showed how sequential treatments, 
consisting in 12 hours of maintained dasatinib followed 
by 72 hours of PEM, were able to almost abrogate TS 
promoter activity. The co-transfection of TS promoter 
and SRC KD (K295M) demonstrated that this regulation 
is mainly mediated by SRC, affecting also TS protein 
levels. This data suggest a dasatinib regulation, through 
SRC inhibition, on those transcription factors having 
responsive elements in the region of TS promoter here 
adopted. Among these putative transcription factors, 
Sp1, GABP and LSF were found to be regulated by 
SRC activation, through ERK signaling [23–25]. 
Further investigation to establish the main TS promoter-
responsive region and corresponding transcription factors 
involved in this regulation are clearly needed. The 
activity of dasatinib in inhibiting SRC family members, 
activating an intracellular signaling that converges on 
mTOR pathway, has been demonstrated in breast cancer 
models [26]. These findings agree with previous in vitro 
studies reporting that the pretreatment with rapamycin 
increases PEM activity reducing TS protein expression 
[27]. The enhanced efficacy of dasatinib in REN cells 
could be also related to its LKB1 null phenotype, which 
influences dTTP metabolism [28] and AMPK-mTOR 
deregulation [15]. This suggests that the loss of LKB1, 
reducing AMPK activation, makes cells more sensitive 
to dasatinib which, in turn, induces cellular stress and 
downregulates both p70S6K and Akt phosphorylation. 
Figure 4: Dasatinib pretreatment effects on apoptosis, target expression and PI3K-Akt-mTOR pathway. Upon 
single agents (PEM and dasatinib), combination and sequential treatments characterized by both, removal (rD→PEM) and maintained 
(mD→PEM), dasatinib pretreatment apoptosis rate was evaluated. Single and combined treatments were performed for 72 hours, sequential 
administrations at 72 (dasatinib pretreatment) + 72 hours (PEM incubation). The data are the results of three independent biological 
experiments for each concentration setting (IC50 & 100 nM) (A). TS and SRC genes expression was assessed for all the conditions tested 
in the study: IC50 (red) and 100 nM (blue). While TS gene was upregulated when sequential treatments with IC50 doses of both drugs were 
employed, the modulation of SRC gene expression more pronounced at 100 nM dose (B). Both, combined and mD→PEM treatments at 
IC50 values downregulated the expression and the activation of the PI3K-AKT-mTOR signaling players analysed. Noteworthy, none of the 
conditions assayed was able to reduce TS expression levels. On the contrary sequential treatments, at 100 nM, led to TS downregulation 
(r = rD; m = mD) (C). 
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Conversely, mTOR phosphorylation is increased, most 
likely due to missed AMPK activation, in the biological 
attempt to maintain homeostasis [29]. PEM leads to AMP-
analog accumulation, which necessarily requires LKB1 
for AMPK activation [15]. In micro-environmental stress 
conditions (including compromised mTOR downstream 
signaling activation and lower TS levels), the addition of 
PEM, upon dasatinib exposure, triggers downregulation 
of mTOR phosphorylation and PI3K p110-α expression, 
leading to both protein synthesis deficiency and inhibition 
of proliferation stimuli. 
Src family kinase (SFK) is a group of nine non-
receptor tyrosine kinases, including, beyond SRC, three 
members (Yes, Fyn, and Lyn) previously identified as 
pivotal players in mesothelioma [30, 31]. Dasatinib 
reduced SRC phosphorylation without significant changes 
in other SFK members’ expression, except in REN cells, 
where it induced also a reduction of Lyn expression (data 
not shown). Previously reported data in a Fyn-deficient 
MPM cell line showed a decreased Lyn expression 
following PP2 administration, a SFK inhibitor, which 
also affected apoptotic induction [30]. PEM and dasatinib 
synergistically inhibited cell proliferation in all cell 
lines, while induction of apoptosis was more evident in 
REN and MPP89 cells and less in MSTO. According to 
previous studies in MSTO cells [16], the combination of 
PEM with vandetanib led to a minimal apoptotic effect 
compared with PEM alone, most likely due to the low 
TS expression in this biphasic cell line. In REN cells, 
the higher apoptotic effect of PEM and dasatinib co-
treatment was associated with a more intense cytotoxic 
effect, including suppression of PI3K p110-α (but not the 
β isoform) subunit expression, and reduction/suppression 
of SRC, Akt, p70S6K phosphorylation. Unfortunately, the 
main effect of this pharmacological stimulation consists 
in the up-regulation of TS expression levels suggesting 
that TS increase could be the adaptive cellular response to 
high dose PEM exposure. Dasatinib at 100 nM inhibited 
SRC phosphorylation, reduced both TS promoter activity 
and protein expression; in the sequential mD treatment 
testing PEM at 100 nM dose a lack of the compensating 
cell response was observed, with no TS up-regulation and 
with induction of apoptosis. At the tested concentration, 
dasatinib already acts on Akt phosphorylation, as 
previously reported [16, 32, 33]. In addition, mD condition 
reduces PI3K-p110-α subunit expression, as well as 
suppress both mTOR and p70S6K phosphorylation: the 
dependence of p70S6K phosphorylation from SRC has 
been previously demonstrated through the ability of 
the SRC-specific inhibitor SU6656 to reduce p70S6K 
phosphorylation [34].
In conclusion, our data in MPM cell lines 
demonstrate that the pretreatment with dasatinib sensitizes 
PEM activity through SRC inhibition, even at low 
concentrations of both drugs, impairing cell migration, 
affecting TS promoter regulation and decreasing TS 
protein, with consequent increase of PEM sensitivity. 
Sequential administration of the two agents, also at low 
doses, enhanced the synergistic effect observed, with 
inhibition of TS protein up-regulation and increased PEM 
cytotoxic activity.  Based on these results, future in vivo 
studies will be planned and new treatments schedules 
designed to maximize the efficacy of combo treatment.
MATERIALS AND METHODS
Cell culture
Three human MPM cell lines (MSTO-211H, NCI-
MPP89, and REN) were used: MSTO-211H (designated 
MSTO) and MPP89 were purchased from Interlab Cell 
Line Collection (Genova, Italy), while REN [35] cells 
were kindly provided by Dr. Moro (University of Novara, 
Italy) and Dr. Albelda (University of Pennsylvania, 
Philadelphia, USA). Cells were grown in monolayer 
cultures in RPMI 1640 containing 10% fetal bovine serum, 
2 mM glutamine, and 5% Penicillin/Streptomycin at 37°C 
humidified atmosphere of 95% air and 5% CO2. 
Reagents and drugs
Dasatinib [BMS-354825, Bristol-Myers Squibb] 
was purchased by LC Laboratories (Woburn, MA, 
USA) and was prepared as a 10 mmol/L stock solution 
in DMSO. Pemetrexed [ALIMTA] was kindly provided 
by Eli Lilly Corporation (Indianapolis, IN, USA) and 
was dissolved in Hanks’ balanced salt solution as a 
60 mmol/L stock solution. Preliminary cell culture 
tests have shown that DMSO (Volume 0.2% was the 
maximum amount used to deliver dasatinib) has no effect 
on cell viability, cell cycle, apoptosis, or signaling (data 
not shown).
For Western blot analysis the following antibodies 
were used: cSrc (32G6), pSrc, (Tyr419) (D49G4); 
phosphoinositide 3-kinase (PI3K) p110α subunit (C73F8), 
PI3K p110β subunit (C33D4) and phospho-ribosomal 
protein S6K (p-p70S6K [Thr389]) from Cell Signaling 
Technology (Danvers, MA, USA); Beta-actin (C4); 
Vinculin (N-19), pAkt1/2/3 (11E6) and Akt (all from Santa 
Cruz Biotechnology, Dallas, TX, USA ); Thymidylate 
Synthase (TS) (EPR4545), mammalian target of 
rapamycin (mTOR (ab2732)), from AbCam (Cambridge, 
UK). Horseradish peroxidase (HRP)-conjugated donkey-
anti-goat IgG was from Santa Cruz Biotechnology, HRP-
goat-anti-mouse and HRP-goat anti-rabbit polyclonal 
IgG were from AbCam. For apoptosis assay, Annexin 
V- fluorescein isothiocyanate (FITC) was purchased from 
BD Biosciences (San Jose, CA, USA), PI (propidium 
iodide) from Life Technologies (Carlsbad, CA, USA); for 
immunofluorescence, FITC-labelled anti-rabbit secondary 
antibody from Jackson Immuno Research (West Grove, 
PA, USA).
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Immunofluorescence microscopy 
For immunofluorescence analyses, cells were grown 
on glass coverslips following the procedure previously 
described [36], except for fixation method employed 
in this study, consisting in 4% paraformaldehyde/PBS. 
Confocal series images were taken on an inverted Zeiss 
LSM510 microscope equipped with a Plan-Apochromat 
63X/1.4 oil immersion Ph 3 objective (Oberkochen, 
Germany). Scale bars: 10 μm. Each experiment was 
performed in duplicate.
Cell viability (MTS assay)
For standard cell culture maintenance, cells were 
seeded in 96-well plates for 24 hours under the above 
indicated conditions, then treated with this range of 
increasing concentrations (10 nM, 100 nM, 1 µM, 10 µM, 
100 µM and 1 mM) of PEM (A) or dasatinib  (B), either 
as single agents or in combination (ratio 1:1 for each 
drug concentration) and incubated for 48 and 72 hours. 
Additionally, in REN cell line, sequential administration of 
the two agents was also investigated, as follows: cells were 
incubated with dasatinib for 72 hours, then dasatinib was 
washed out (rD) and PEM added for additional 72 hours 
at the increasing concentrations reported above (C); in 
another set of experiments, dasatinib was maintained 
(mD) in cell culture and PEM added for 72 hours (D). 
Four technical replicates and three biological replicates 
for each treatment/cell line were performed.
After exposure of cell lines to drugs, an 
[3-(4-5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)- 
2-(4-sulfophenyl)-2H-tetrazolium, inner salt MTS assay 
(Promega, Madison, USA) was performed according to 
the manufacturer’s instruction. Absorbance was measured 
at 490 nm with EnSpire Multimode Plate Readers (Perkin 
Elmer, Waltham, Massachusetts). Due to cytostatic effect 
of both drugs, when administered as single agents (except 
in MSTO cell line, where PEM showed cytotoxic effect 
already at 48 hours), the determination of inhibitory 
concentration of 50% of cells (IC50) was not always 
possible. On the contrary, when the two drugs were used 
in combination, the administration produced a cytotoxic 
behavior, demonstrating strong synergy of the two drugs. 
For this purpose, in each cell line and for both drugs, we 
called “PEM IC50” and “dasatinib IC50” the corresponding 
drug doses which, in combination, were able to inhibit 
50% of cells. These values were obtained by means of the 
GraphPad software (La Jolla, CA, USA).
 Apoptosis assay
Apoptosis was evaluated in sub-confluent cells 
treated as reported above and single agent or combinations 
were added for 48–72 hours. After incubation, cells were 
harvested (supernatant and adherent cells), washed twice 
with 1X PBS, re-suspended in 1X Binding solution 
(100 mM HEPES, pH 7.4; 140 mM NaCl; 2.5 mM 
CaCl2) and then stained with Annexin V-FITC and PI. 
The following controls were used to set up compensation 
and quadrants: unstained cells, cells stained with Annexin 
V-FITC alone (no PI), cells stained with PI alone (no 
Annexin V-FITC). After 15 minutes of incubation in 
the dark, cells were analyzed on a cytofluorimeter by 
fluorescence activated cell sorting analysis (CyAn™ ADP 
Analyzer - Beckman Coulter; CA, USA) using Summit 
4.3 software.
Migration assay (wound healing-scratch assay)
MPM cells were grown to confluence on 6-well 
dishes, and then three separate scrapes for each well were 
made in the confluent monolayer using a sterile pipette 
tip. The monolayer was washed with 1X PBS, then 
complete medium containing the corresponding IC50 of 
dasatinib (IC50 values included in Figure 2A), alone or in 
combination with PEM, was supplied. DMSO alone acted 
as control. Serial photographs of the same scraped section 
were captured every 6 hours for 30 hours. The width of 
scratch, over the margins of the wounds, was measured (in 
pixel values) at the beginning and at regular intervals of 
6 hours and then plotted on a graph, to quantify the cells 
migration rate. The time required for the scrape to heal, in 
each cell line, was also recorded.
RNA extraction and gene expression analysis
RNA was extracted with Trizol (Qiagen) following 
manufacturer’s instructions. Each sample was quantified 
using spectrophotometer and 1 µg of RNA was 
retrotranscribed as previously described [36]. Genomic 
DNA contamination was removed by DNAse I treatment, 
according to manufacturer’s protocol (Ambion, Life 
Technologies, Carlsbad, CA, USA). Relative cDNA 
quantification was performed using a fluorescence-
based real-time detection method with measurements 
done in triplicate and the comparative Ct method used, 
as previously reported [37]. Quantitative Real Time 
polymerase chain reaction (qPCR) was performed with 
an ABI PRISM 7900HT Sequence Detection System 
(Applied Biosystems, Life Technologies) in 384-wells 
plate and SRC primers and probe used were previously 
reported [13]. For the other genes, exon-spanning TaqMan 
Gene Expression Assays were used, including TS (TYMS; 
Hs00926279_g1) and GUSB (GUSB; Hs99999908_m1). 
Each qPCR reaction was performed in technical triplicate 
and reported data represent the median value of three 
independent biological experiments. 
Western blot and alpha technology analysis
From each cell culture plate, adherent cells were 
washed with 1X PBS, detached using 1X PBS-0.01% 
EDTA buffer and collected by centrifugation. The 
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obtained pellet was rinsed with ice-cold 1X PBS and 
lysed for 30 min on ice, vortexing at 10 minute intervals. 
Extraction cell-lysis buffer was used (Invitrogen, Life 
Technologies). 100X Protease Inhibitors Cocktail 
(P8340, Sigma Aldrich, Saint Louis, MO, USA) and 
100X Phosphatase Inhibitor Cocktail 2 (P5726, Sigma 
Aldrich) were adequately added to lysis buffer. Lysates 
were spun in a centrifuge at 13,700 rpm for 10 minutes 
at 4°C and the clear supernatant collected. Bicinchoninic 
acid (BCA, Sigma Aldrich) assay was used to determine 
protein concentration in each sample and equal protein 
aliquots (40 µg) were resolved by SDS-PAGE, transferred 
to nitrocellulose membranes, immuno-blotted with 
adequate primary antibodies, detected with horseradish 
peroxidase–conjugated secondary antibodies and revealed 
by enzymatic chemiluminescence reagent (Millipore, 
Merck KGaA, Darmstadt, Germany). 
To measure the phosphorylation of endogenous 
mTOR in cellular lysates, a quantitative assay that 
employs the bead-based Alpha Technology [AlphaScreen 
SureFire mTOR (p-Ser2448) assay kit (Perkin Elmer, 
Waltham, MA, USA)] was used. To this purpose, 
according to the manufacturer’s instructions, also total 
mTOR protein expression was investigated by western 
blotting. This allowed normalizing the results obtained 
on phosphorylated mTOR, comparing the two different 
expression levels.
Stable transfections: engineering of REN-
derived clones expressing luciferase gene under 
control of TS promoter
To evaluate the ability of different drugs 
(Dasatinib and PEM) to modulate TS gene expression, 
we engineered the pGL4.14[luc2/Hygro] plasmid 
(Promega) with a genomic fragment extract from TS 
locus by PCR.  The genomic fragment correspond to a 
region, including the transcription-starting codon ATG, of 
the TS promoter (from nucleotide –1191 to +176). This 
fragment was amplified using primers: TYMS.–1191.FW 
(AATTGGATCCTAAAACTGGGAAATGTGGTCTATTA 
AAA) and TYMS.+176.RW (AATTAAGCTTGAATACC 
GACAGGGTGCCG). The PCR was performed with 
GoTaq Flexy kit (Promega) in buffer containing: 100 ng 
REN genomic DNA, Taq Buffer 1x, 1.5 mM MgCl2, 
1 µM primers, 1.25 u Taq and 10% DMSO. The purified 
fragment was cloned in pGEMt-easy (Promega) to create 
pGEMt-TS-Promoter (pGEMt-TS-Prom) plasmid. From 
this plasmid was cut the region of TS promoter by BAM-
HI/HIND III and subsequently cloned in pGL4.14[luc2/
Hygro] linearized with BGL II/HIND III generating 
plasmid pGL4-TS-Prom-1191 + 176. One day prior 
to transfection, REN cells (1.5 × 105 cells/well) were 
seeded into a 6-well tissue culture plate and cultured 
with 2 mL fresh complete RPMI-1640 medium. Cells 
were then transfected with DreamFect (OZ Biosciences, 
SAS, Marseille, France) using 1 µg of pGL4-TS-
Prom-1191+176 per well according to manufacturer’s 
instructions. After transfection, cells were cultured 
for 48 hours and subsequently selected by 600 µg/ml 
Hygromycin b. After 2 weeks incubation with antibiotic, 
cells were diluted to single cell clones and cultured in 
presence of 400 µg/ml Hygromycin b. Several clones 
expressing luciferase under control of TS promoter (D7, 
D9, D2, C8, A7) were analyzed by luminometer (Enspire; 
Perkin Elmer) and were employed to quantify the response 
of TS promoter to dasatinib, PEM and drugs combination. 
Transient transfections: luciferase assays with 
TS promoter and SRC dominant negative 
K295M (KD) constructs 
A DNA fragment containing the full length Gallus 
Gallus SRC KD K295M sequence was extracted by XbaI 
from plasmid SG5-SRC-KD and was cloned in pcDNA-3(-) 
generating plasmid pcDNA-SRC-KD-K295M. The day 
before transfection, REN cells (2 × 105 cells/well) were 
seeded into a 6-well tissue culture plate and cultured with 
1.5 mL fresh complete RPMI-1640 medium. Cells were 
then transfected with JetPrimer (PolyPlus, Strasbourg, 
France) using 2 µg of plasmid 1:10:1 combinations: 
pGL4-TS-Prom-1191+176/TK-renilla/pdDNA 3 or pGL4-
TS-Prom-1191+176/TK-renilla/pcDNA-SRC-KD-K295M 
per well according to manufacturer’s instructions. After 
transfection, cells were cultured for 24 or 48 hours. After 
incubation the cells were lysed by Passive Lysis Buffer 
(Promega) and luminescence measured by luminometer 
(Enspire). All experiment was performed at least in 
duplicate for tree times, each firefly luciferase signal was 
normalized by renilla luciferase and the normalized values 
was relativized to pcDNA transfection.
Next-generation sequencing (NGS)
Genomic DNA (gDNA) was extracted using 
Wizard® Genomic DNA Purification Kit (Promega) 
following the manufacturer’s instructions. gDNA was 
quantified using fluorometer Qubit platform (Invitrogen, 
Carlsbad, CA). NGS analyses were performed on the 
Ion Torrent Personal Genome Machine (PGM, Life 
Technologies, Grand Island, USA). Cell lines were tested 
with a commercial library kit (Ion AmpliSeq Cancer 
Hotspot Panel v.2, CHP2) and the NGS procedure was 
previously published [38].
Statistical analysis
Statistical significance of the observed differences 
in drug-treated and untreated cells was analyzed fitting 
data to sigmoidal dose-response curve using GraphPad 
Prism software version 5.0 c. Unpaired t-tests for the 
differences in log IC50 for PEM alone and in combination 
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with dasatinib were significant in all experiments with 
p-value < 0.001.
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